Berrouschot Jörg, Röther Joachim, Glahn Jörg, Kucinski Thomas, Fiehler Jens, Thomalla Götz
The Neurologische Klinik, Kreiskrankenhaus Altenburg, Altenburg, Germany.
Stroke. 2005 Nov;36(11):2421-5. doi: 10.1161/01.STR.0000185696.73938.e0. Epub 2005 Oct 6.
Information on safety and efficacy of intravenous thrombolysis with tissue plasminogen activator (tPA) (IV-tPA) in very old acute ischemic stroke (AIS) patients is scarce. We studied outcome and severe hemorrhagic complications in patients aged 80 and older.
We analyzed data of AIS patients, treated with IV-tPA, in 3 German stroke centers. Neurologic deficit on admission was assessed using the National Institutes of Health Stroke Scale (NIHSS). Outcome was assessed after 90 days using the Modified Rankin Scale (MRS), and favorable outcome was defined as a MRS score of 0 to 1. Severe intracerebral bleeding complications were assessed on follow-up magnetic resonance imaging or cranial computed tomography. Data were compared between patients <80 years of age and patients aged > or =80 years.
A total of 228 patients were treated with IV-tPA; 38 (16%) were 80 years or older. There was no difference in NIHSS on admission or onset to treatment time between younger and older patients. Less patients > or =80 years of age achieved a favorable outcome (26.3 versus 46.8%, P=0.021), and mortality was higher in older patients (21.1 versus 5.3%, P=0.004). There was no difference in the rate of parenchymal hemorrhage (6.3%<80 years versus 5.3%> or =80 years, P=1.000) and symptomatic intracerebral hemorrhage (2.6%<80 years versus 2.6%> or =80 years, P=1.000) between both groups.
There is no increase in severe intracerebral hemorrhage after IV-tPA in very old patients, but outcome is worse as compared with younger patients. There is no evidence to exclude ischemic stroke patients from thrombolysis based on a predefined age threshold.
关于组织型纤溶酶原激活剂(tPA)静脉溶栓治疗(IV-tPA)在高龄急性缺血性卒中(AIS)患者中的安全性和有效性信息匮乏。我们研究了80岁及以上患者的预后及严重出血并发症情况。
我们分析了德国3个卒中中心接受IV-tPA治疗的AIS患者的数据。入院时的神经功能缺损采用美国国立卫生研究院卒中量表(NIHSS)进行评估。90天后采用改良Rankin量表(MRS)评估预后,良好预后定义为MRS评分为0至1分。通过随访磁共振成像或头颅计算机断层扫描评估严重脑出血并发症。对年龄小于80岁的患者和年龄大于或等于80岁的患者的数据进行比较。
共有228例患者接受了IV-tPA治疗;38例(16%)年龄在80岁及以上。年轻患者和老年患者入院时的NIHSS评分或发病至治疗时间无差异。年龄大于或等于80岁的患者中获得良好预后的较少(26.3%对46.8%,P = 0.021),老年患者的死亡率更高(21.1%对5.3%,P = 0.004)。两组间脑实质出血率(年龄小于80岁者为6.3%,年龄大于或等于80岁者为5.3%,P = 1.000)和症状性脑出血率(年龄小于80岁者为2.6%,年龄大于或等于80岁者为2.6%,P = 1.000)无差异。
高龄患者接受IV-tPA治疗后严重脑出血并未增加,但与年轻患者相比预后更差。没有证据表明基于预先设定的年龄阈值将缺血性卒中患者排除在溶栓治疗之外。